

**LSU HSC-New Orleans Institutional Biosafety Committee  
 Ad Hoc Meeting Minutes**

**Date:** Wednesday, March 18, 2026  
**Time:** 2:00PM-2:40PM  
**Location:** Zoom

- Members present:**
1. Zea, *IBC Chair*
  2. Catling, *IBC Vice Chair*
  3. Pourciau, *BSO Alternate*
  4. Caro, *Animal Containment*
  5. Aiyar
  6. Baker
  7. Curran, *Local Non-affiliated Member*
  8. Siggins
  9. Wang
  10. Yue
  11. Zabaleta

- Members excused:**
1. Didier Mejia, *BSO*
  2. Guidry, *Local Non-affiliated Member*

- Other Individuals in Attendance:**
1. Landry, *Research Compliance Analyst II, IBC/IACUC*
  2. Fuselier, *Research Compliance Analyst II, IACUC/IBC*
  3. Burkett, *Affiliated EH&S*

2:00pm **Quorum Present**  
 The IBC has 12 voting members and 6 are required to conduct business

2:00pm **Call to Order**  
 The IBC Chair called the meeting to order

2:01pm **Conflicts of Interest**  
 The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

- **Full Committee Review of applications subject to *NIH Guidelines and our Policies*. Continuing IBC oversight required.**

2:03pm	<b>IBC #10465</b>	<b>Murine R61 IBC Humanized nectin mouse model for oHSV therapy for Cancer Immunology and Immunotherapy</b>
	<b>PI Name</b>	Kaur, Balveen
	<b>Project Overview</b>	This project studies a type of cancer treatment called oncolytic viruses, which are designed to selectively infect and destroy cancer cells while leaving normal cells unharmed. These therapies are already approved in some countries for certain cancers, and this research aims to improve their effectiveness. The study will evaluate new versions of these viruses and test them alone or in combination with existing approved drugs to enhance cancer treatment outcomes. Researchers will also investigate how tumors may resist

	this therapy and identify ways to overcome that resistance. The goal is to support the development of safer and more effective virus-based cancer treatments.
<b>NIH Guidelines Section(s)</b>	III-D-1-a III-D-2-a Section III-F-8, Appendix C-VII Section III-F-8, Appendix C-VIII III-E-1 III-E-3-a III-F-3
<b>Risk Assessment &amp; Discussion</b>	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, and lab coats or disposable gowns. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
<b>Training</b>	All institutional trainings required are complete for lab staff listed in the registration: <ul style="list-style-type: none"> <li>• COI in Research</li> <li>• Laboratory Safety</li> <li>• IBC Compliance</li> <li>• BBP High Risk</li> </ul>
<b>EH&amp;S Assessment</b>	The laboratory was inspected, and any identified deficiencies will be addressed prior to the initiation of research activities.
<b>Occupational Health Representative review (if applicable)</b>	N/A
<b>Biosafety Level Assignment</b>	BSL-2 ABSL-2
<b>IACUC status (if applicable)</b>	Application under review
<b>IBC Vote</b>	The Primary Reviewer made a motion to assign the determination of Defer for Information. <ul style="list-style-type: none"> <li>• <b>Votes:</b> 10/11 Defer for Information              1/11 MRSA</li> <li>• <b>COI:</b> None reported</li> </ul> Following a duly called vote of the committee, Dr. Kaur’s protocol was Deferred for Information, pending submission of the requested revisions. The revised protocol will be reviewed and must receive approval by the Full Committee.

2:40pm **Adjournment**

The IBC Chair moved to adjourn the meeting at 2:40PM. The next meeting is tentatively scheduled for Wednesday, April 8, 2026, via Zoom.